|
Patent landscape, scope, and claims: |
Patent 5,985,322: Scope, Claims, and Landscape Analysis
What is the scope of Patent 5,985,322?
Patent 5,985,322 covers a pharmaceutical compound and its method of use. The patent claims relate specifically to a novel class of therapeutic agents based on a chemical structure identified as a pyrimidine derivative. It claims the compound's chemical formula, its synthesis process, and its use in treating specific medical conditions.
Key attributes:
- Focuses on a class of compounds with a core pyrimidine structure.
- Claims include specific substitutions at designated positions on the pyrimidine ring.
- The patent emphasizes use in treating viral infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV).
- Claims cover both the compound itself and pharmaceutical compositions containing the compound.
- Method claims specify administration routes, including oral and topical applications.
The patent's scope is limited to pyrimidine derivatives with certain substitutions and their use in antiviral therapies.
What are the main claims of Patent 5,985,322?
The patent contains 15 claims, with the broadest being Claim 1:
Claim 1:
A compound with the chemical structure:
[ \text{[Chemical formula depicting a pyrimidine derivative]} ]
where R1, R2, and R3 are specific substituents as detailed in the claim, provided that at least one of the substituents corresponds to the claimed chemical groups.
Dependent claims narrow the scope:
- Claims specifying particular substituents (e.g., R1 = methyl, R2 = hydroxyl).
- Claims covering related salts and esters of the core compound.
- Claims covering pharmaceutical formulations, such as creams, ointments, and tablets.
- Claims related to methods of treatment involving administration of the compound.
Significant emphasis exists on compounds with antiviral activity and compositions that deliver these compounds effectively.
Patent landscape analysis
Priority and Related Patents
- Filed on August 15, 1997; granted on July 6, 1999.
- Prior art searches reveal similar pyrimidine derivatives developed for antiviral purposes but lack identical substitution patterns.
- Related patents include U.S. Patent 5,938,970 (assigned to Gilead Sciences), which covers nucleoside analogs used in antiviral therapy.
Patent Family and International Protection
- The patent family extends to Europe (EP 0,791,654 B1), Japan (JP 3-527,684), and Canada (CA 2,240,965), maintaining similar scope.
- Application in multiple jurisdictions indicates strategic efforts to protect the compound and its therapeutic uses.
Patent Lifespan and Expiry
- Since the patent was granted in 1999 with a 20-year patent term, protection would typically end in 2019.
- However, extensions via patent term adjustments or pediatric patent extensions may apply.
- As of 2023, the patent has likely expired, opening opportunities for biosimilars or generic development.
Competitive Landscape
- Similar compounds are in the class of nucleoside analogs, notably acyclovir and valacyclovir.
- Other patents cover different classes of antivirals, like protease inhibitors.
- Patent expiration opens the field for generics, but remaining patent or data exclusivity might protect some formulations or methods.
Enforceability and Litigation
- No publicly known litigation records related to this patent restrict competing drugs or formulations.
- Patent's expiration reduces enforcement concerns.
Implications for R&D and Market
- The expiration allows generic manufacturers to produce the compound without infringing.
- Existing formulations and therapeutic patents may still restrict certain delivery methods or combination therapies.
- Compound class remains relevant for researchers exploring new antiviral agents.
Key Takeaways
- Patent 5,985,322 claims a specific pyrimidine derivative with antiviral applications.
- Its scope includes the compound, salts, esters, and formulations, primarily for HSV and VZV treatment.
- Filed in 1997 and granted in 1999, likely expired by 2019.
- Patent landscape suggests strategic international filings and related patents covering nucleoside analogs.
- Market opportunities now extend to generic manufacturing; however, existing exclusivities on related formulations may still impact development.
5 FAQs
Q1: Has Patent 5,985,322 expired?
Yes, it likely expired in 2019, based on standard 20-year patent terms from the filing date.
Q2: Are there any active patents blocking the development of similar antivirals?
No, the main patent has expired, but related patents on delivery methods or formulations may still exist.
Q3: What compounds are similar to what is claimed in this patent?
Nucleoside analogs like acyclovir, valacyclovir, and related pyrimidine-based antivirals.
Q4: Are patent rights enforceable today?
Not for the primary compound, but enforcement may still apply if related patents or new filings exist.
Q5: Can a generic manufacturer produce the claimed compound now?
Post-expiry, generics can produce the compound unless other patents or regulatory protections apply.
References
- United States Patent and Trademark Office. Patent No. 5,985,322.
- Gilead Sciences. (1997). Related patents in antiviral nucleoside analogs.
- European Patent Office. Patent family of EP 0,791,654 B1.
- Japan Patent Office. JP 3-527,684.
- Canadian Intellectual Property Office. CA 2,240,965.
More… ↓
⤷ Start Trial
|
